You are here

Home » Content

Malign Melanomda Tedavi Prensiplerimiz ve Sonuçlarımız

Our Treatment Principles and Results in Malignant Melanoma

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
In this study, our experiences with 30 cases who were treated for melanoma between the years 1993-2001 in the Department of Plastic and Reconstructive Surgery of Uludağ University Medical School were presented. These cases were evaluated according to the age, sex, localization, histologic type and level, nodal status and recurrence. Eighteen cases were men and 12 cases were women. The mean age was 61 years. Histologic examinations revealed that 17 cases were nodular, 6 cases were superficial, 4 cases were acral lentiginous and 3 cases were lentigo melanoma. According to the Clark's level, 43.3% of the cases were classified in level IV-V, 13.3% in level III and 43.3% in level II. At the admission, 53.3% of the cases were found to have regional lymph node metastasis. Local recurrence was seen in 10% of the cases at different time points following the operation. We excised the lesions with 3-cm free margin including the fascia. Regional lymph node dissection was performed in cases who had regional lymph node metastatis. In cases who had no lymph node metastasis, sentinel lymph node biopsy was performed.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, 1993-2001 yılları arasında, Uludağ Üniversitesi Tıp Fakültesi Plastik ve Rekonstrüktif Cerrahi Kliniğinde opere edilen 30 malign melanomlu olgu ile ilgili deneyimlerimiz sunulmaktadır. Olgular yaş, cinsiyet, lezyonun yerleşimi, histolojik tipi ve evresi, lenf nod tutulumu ve nüks dikkate alınarak incelendi. Onsekizi erkek, 12’si kadın hasta olan olguların yaş ortalaması 61'dir. Histolojik incelemeler sonucunda, 17 olguda nodüler tip, 6 olguda yüzeyel yayılan tip, 4 olguda akral lentiginöz tip ve 3 olguda lentigo tip malign melanom saptandı. Clark'ın yaptığı evrelendirmeye göre; %43.3’ü evre IV ve V, % 13.3’ü evre III ve %43.3’ü evre II olarak tespit edildi. Olguların %53,3’ünde başvuru sırasında bölgesel lenf nod tutulumu saptanırken, olguların %10’unda operasyon sonrasında değişik zamanlarda lokal nüks görüldü. Bu çalışmada, malign melanomlu olguların lezyonları 3 cm salim doku ile birlikte fasya da dahil edilmek üzere eksize edildi. Bölgesel lenf nod metastazı saptanan olgularda lenf nodu disseksiyonu yapılırken, bölgesel lenf nod metastazı olmayan olgularda ise sentinel lenf nodu biopsisi yapıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-malign-melanomda-tedavi-prensiplerimiz-sonuclarimiz.pdf
  • 1
13-16
  • Turkish

REFERENCES

References: 

1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1512
melanoma patients with distant metastases. J Am Coll Surg
1995;181:193-201.
2. Landis SH, Murray T, Bolden S et al. Cancer statistics 1998.
CA Cancer J Clin 1998;48:1-29.
3. Parker SL, Tong T, Bolden S et al. Cancer statistics 1996. CA
Cancer J Clin 1997;47:5-27.
4. Chang AE, Karnell LH, Menck HR. The national cancer data
bese report on cutaneous and non-cutaneous melanoma: a
summary of 84.836 cases from past decade. Cancer
1998;8:1664-78.
5. Brodsky I, Baren M, Kahn SB et al. Metastatic malignant
melanoma from mother to fetus. Cancer 1965;18:1048-54.
6. Bale SJ, Dracopoli NC, Tucker MA et al. Mapping the gene for
hereditary cutaneous melanoma. N Engl J Med
1989;320:1367-72.
7. Liu L, Lassam NJ, Slingerland JM et al. Germline P16 INK4A
mutation and poretin dysfunction in a family with inherited
melanoma. Oncogene 1995;11:405-12.
8. Kopf AW, Kripke ML, Stern RS. Sun and malignant
melanoma. J Am Acad Dermatol 1984;11:674-84.
9. Osterlind A, Tucker MA, Stone BJ et al. The Danish casecontrol study of cutaneous malignant melanoma. The
importance of UV-light exposure. Int J Cancer
1988;42:319-24.
10. MacKie RM, Aitchison TC. Severe sunburn and subsequent
risk of primary cutaneous melanoma. Br J Cancer
1982;46:955-60.
11. Ho VC, Sober AJ. Therapy for cutaneous melanoma. An
update. J Am Acad Dermatol 1990;22:159-77.
12. Clark WH, From L, Bernardino EA et al. The histogenesis and
biologic behaviour of primary human malignant
melanomas of the skin. Cancer Res 1969;29:705-26.
13. Reed RJ, Ichinose H, Clark WH, Jr. Common and uncommon
melanocytic nevi and borderline melanomas. Semin Oncol
1975;2:119-47.
14. Clark WH, Jr, Ainsworth AM, Bernardino EA. The
developmental biology of primary human malignant
melanomas. Semin Oncol 1975;2:83-103.
15. Kopf AW, Mintzis M, Bart RS. Diagnostic accuracy in
malignant melanoma. Arch Dermatol 1975;111: 1291-2.
16. Mihm MC, Jr, Clark WH, Jr, Reed RJ. The clinical diagnosis of
malignant melanoma. Semin Oncol 1975;2:115-8.
17. MacKie RM. An aid to the preoperative asssessment of
pigmented lesions of the skin. Br J Dermatol
1971;85:2332-8.
18. MacKie RM. Melanocytic naevi and malignant melanoma. In:
Champion RH, Burton JL, Burns DA, Breathnach SM
(eds). Textbook of Dermatology. 6 th edition. London:
Blackwell Science;1998. 1717-52.
19. Richards JM, Mehta N, Ramming K et al. Squential
chemoimmunotherapy in the treatment of metastatic
melanoma. J Clin Oncol 1992;10:1338-43.
20. Hanka-Kemppinen M, Muhanen T, Virolainen M et al.
Response of subcutaneous and cutaneous metastases of
malignant melanoma to combined cytostatic plus interferon
therapy. Br J Dermatol 1995;132:973-7.
21. Breslow A. Thickness, cross-sectional areas and depth of
invasion in the prognosis of cutaneous melanoma. Ann
Surg 1970;172:902-8.
22. Veronesi U et al. Thin stage 1 primary cutaneous malignant
melanoma: Comparison of excision with margins of 1 or 3
cm. N Eng J Med 1988;318:1159-62.
23. Bauer R, Kopald K, Lee J et al. Long-term results of
intralesional BCG for locally advanced recurrent
melanoma (abstract). Proc Am Soc Clin Oncol 1990;9:276.
24. Robinson WA, Mughal TI, Thomas MR et al. Treatment of
metastatic malignant melanoma with recombinant
interferon alpha 2. Immunology 1986;172: 275-82.
25. Legha S, Ring S, Bedikian A et al. Treatment of metastatic
melanoma with combined chemotherapy containing
cisplatin, vinblastine and dacarbazine (DTIC) and
biotherapy using interleukin-2 and interferon-alpha. Ann
Oncol 1996;7:827-35.

Thank you for copying data from http://www.arastirmax.com